Medipol develops next generation immunotherapeutic treatments with broad applications against infectious disease (flu, influenza), cancer, genetic disorders and biodefense threats. The company's technology platform is a result of more than 15 years of academic research at Swiss academic institutions and more than CHF 3 million of research investment by Medipol working on diseases related to the immune system. It is capable of induceing the critical cellular immune response and is therefore expected to play a key role in the expanding global vaccine market.

The milestones achieved by Medipol since its foundation in 2003 include

• an outstanding in vivo-optimized cell targeting technology platform Hynosphere^TM protected by several patent families
• strategic partnerships with pharma
  companies
• steadily growing sales revenues
• a highly committed investor base
• public recognition through numerous awards and prizes

Thanks to its energetic and goal-oriented team focused on patient benefits, Medipol is on the threshold of entering clinical development for its lead drug candidate.